» Articles » PMID: 24015338

Circulating Angiogenic Modulatory Factors Predict Survival and Functional Class in Pulmonary Arterial Hypertension

Abstract

The diagnosis of pulmonary arterial hypertension (PAH) is frequently delayed. We hypothesized that circulating angiogenic modulatory protein levels might correspond with vascular remodeling activity and serve as sensitive biomarkers of PAH. Levels of soluble endoglin (sEng), soluble vascular endothelial growth factor receptor-1 (sVEGFR1), N-terminal brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), and other biomarkers were measured in peripheral blood from 97 PAH patients, 16 first-degree relatives of idiopathic or heritable pulmonary arterial hypertension (HPAH) patients, and 56 controls, and correlated with disease, functional class, hemodynamic parameters, exercise capacity, and transplant-free survival. Endoglin expression was analyzed in lung tissues of six individuals with idiopathic or HPAH and four individuals without PAH. Levels of sEng, sVEGFR1, CRP, and NT-proBNP were elevated in Group I PAH of diverse etiologies, with sEng performing better than NT-proBNP in detecting PAH (receiver operator characteristic-area-under-the curve [ROC-AUC] of 0.82 ± 0.03 vs. 0.71 ± 0.05, P = 0.016). While sEng, sVEGFR1, and NT-proBNP correlated with New York Heart Association (NYHA) class, sEng levels were more sensitive than NT-proBNP in detecting NYHA Class I-II disease (ROC-AUC of 0.88 ± 0.05 vs. 0.67 ± 0.08, P = 0.028). sEng, sVEGFR1, CRP, and NT-proBNP predicted transplant-free survival by univariate Cox regression. After adjusting for NT-proBNP levels, each of the other three markers predicted transplant-free survival. In multivariate analysis, sEng and CRP were independent predictors of survival. Endoglin expression was markedly enhanced in the microvascular endothelium and endovascular lesions of PAH versus control lung tissues. Circulating angiogenic proteins sEng and sVEGFR1 are sensitive markers of prognosis and function in Group I PAH, including mildly symptomatic disease, and may provide unique noninvasive data reflecting underlying remodeling activity.

Citing Articles

Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration.

Blaha V, Rathouska J, Langrova H, Blaha M, Studnicka J, Andrys C Sci Rep. 2024; 14(1):28902.

PMID: 39572693 PMC: 11582623. DOI: 10.1038/s41598-024-80375-5.


Identification of Serum Interleukin-22 as Novel Biomarker in Pulmonary Hypertension: A Translational Study.

Klein F, Dinesh S, Fiedler D, Grun K, Schrepper A, Bogoviku J Int J Mol Sci. 2024; 25(7).

PMID: 38612795 PMC: 11012889. DOI: 10.3390/ijms25073985.


Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?.

Graham B, Hilton J, Lee M, Kumar R, Fonseca Balladares D, Rahaghi F JHLT Open. 2023; 1.

PMID: 38050478 PMC: 10695267. DOI: 10.1016/j.jhlto.2023.100007.


Angiogenesis Redux: An Overall Protective Role of VEGF/KDR Signaling in the Microvasculature in Pulmonary Arterial Hypertension.

Zhong Y, Yu P Arterioscler Thromb Vasc Biol. 2023; 43(10):1784-1787.

PMID: 37675636 PMC: 10803133. DOI: 10.1161/ATVBAHA.123.319839.


Role of micro-RNAs 21, 124 and other novel biomarkers in distinguishing between group 1 WHO pulmonary hypertension and group 2, 3 WHO pulmonary hypertension.

Dimitry M, Soliman Y, Elkorashy R, Raslan H, Kamel S, Hassan E Egypt Heart J. 2023; 75(1):76.

PMID: 37646902 PMC: 10468479. DOI: 10.1186/s43044-023-00395-w.


References
1.
Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H . Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol. 2001; 28(11):2389-91. View

2.
Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A . Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125(17):2128-37. DOI: 10.1161/CIRCULATIONAHA.111.079921. View

3.
Wu F, Stefanini M, Mac Gabhann F, Kontos C, Annex B, Popel A . A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2009; 14(3):528-52. PMC: 3039304. DOI: 10.1111/j.1582-4934.2009.00941.x. View

4.
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6):642-9. DOI: 10.1038/nm1429. View

5.
Kaibe M, Ohishi M, Ito N, Yuan M, Takagi T, Terai M . Serum interleukin-15 concentration in patients with essential hypertension. Am J Hypertens. 2005; 18(8):1019-25. DOI: 10.1016/j.amjhyper.2005.02.014. View